Affiliations: [a]
Cooper University Healthcare at Rowan University, Camden, NJ, USA
| [b]
University of Rochester, Rochester, NY, USA
| [c]
The Ohio State University, Columbus, OH, USA
| [d]
Harvard Medical School, Boston, MA, USA
Correspondence:
[]
Correspondence to: Andrew McGarry, MD, Cooper University Healthcare at Rowan University, 3 Cooper Plaza, Suite 320, Camden, NJ 08103, USA. Tel.: +1 856 342 2445; Fax: +1 856 964 0504; E-mail: mcgarry-andrew@cooperhealth.edu.
Note: [1] These authors contributed equally to this work.
Abstract: Background:Despite the clearly recognized progressive functional decline of Huntington’s disease (HD), detailed investigations of factors associated with the rate of functional progression are limited. Objective:Understanding factors associated with functional decline through examination of existing HD clinical databases may improve efforts to mitigate it. Methods:We analyzed data from 2CARE, a randomized clinical trial with up to 5 years of follow-up, to assess potential risk factors for more rapid functional decline in HD. Results:Variables associated with faster functional decline included worse motor performance, worse cognitive test scores, female sex, lower weight and body mass index, and a higher CAG repeat length, especially in younger people. Conclusion:While our data are limited to the structured environment and homogeneity of a clinical trial, attention to several of the identified risk factors may be useful towards managing functional decline over time. The observation that women progress faster than men, while potentially confounded by an association between sex and weight, deserves further study.
Keywords: Huntington’s disease, clinical trial, functional decline, total functional capacity
